Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Colorectal Carcinoma
|
1962 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.800 | 1.000 | 2 | 2014 | 2019 | ||||||
Inflammatory Bowel Diseases
|
605 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.800 | 1.000 | 1 | 2012 | 2012 | ||||||
Platelet Count measurement
|
457 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.800 | 1.000 | 1 | 2011 | 2011 | ||||||
Malignant neoplasm of lung
|
1142 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.710 | 0.500 | 2 | 2011 | 2018 | ||||||
Serum albumin measurement
|
3282 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 2 | 2012 | 2013 | ||||||
Adenocarcinoma of large intestine
|
432 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 1 | 2019 | 2019 | ||||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1
|
374 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 1 | 2019 | 2019 | ||||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 10
|
370 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 1 | 2019 | 2019 | ||||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 12
|
373 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 1 | 2019 | 2019 | ||||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 3
|
368 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 1 | 2019 | 2019 | ||||||
Colorectal Neoplasms
|
609 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 1 | 2019 | 2019 | ||||||
Crohn Disease
|
1147 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 1 | 2017 | 2017 | ||||||
Fatty acid measurement
|
116 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 1 | 2015 | 2015 | ||||||
Malignant neoplasm of large intestine
|
375 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 1 | 2019 | 2019 | ||||||
Malignant tumor of colon
|
688 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 1 | 2019 | 2019 | ||||||
Phospholipid measurement
|
306 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.700 | 1.000 | 1 | 2011 | 2011 | ||||||
Malignant Neoplasms
|
1641 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.020 | 1.000 | 2 | 2014 | 2019 | ||||||
Primary malignant neoplasm
|
1374 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.020 | 1.000 | 2 | 2014 | 2019 | ||||||
Breast Carcinoma
|
2793 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||||
Carcinoma of lung
|
1204 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.010 | 1 | 2018 | 2018 | |||||||
Childhood Kidney Wilms Tumor
|
36 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
Childhood Leukemia
|
140 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.010 | 1 | 2016 | 2016 | |||||||
Endometriosis
|
274 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
Fuchs Endothelial Dystrophy
|
32 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.010 | 1 | 2018 | 2018 | |||||||
Glioma
|
353 | 0.677 | 0.320 | 11 | 61796827 | 3 prime UTR variant | G/C;T | snv | 0.010 | 1.000 | 1 | 2016 | 2016 |